TeraMedica Debuts New Vendor Neutral Archive
TeraMedica will demonstrate at RSNA 2014 its new vendor neutral archive, Evercore 6.0.
TeraMedica will debut at RSNA 2014 the Evercore 6.0 vendor neutral archive with a new user interface.
Evercore 6.0 supports customizable screen features based on specialized enterprise or departmental needs, TeraMedica said. They also announced that the system features site-specific icons and toolsets that streamline operation by bringing access to key information and user-defined functionalities.
Evercore 6.0 features a new intelligent information presentation, which delivers data directly to users to pare down search time and leverage the VNA for information gathering and analytics, TeraMedica said.
A new IHE profile imaging object change management (IOCM) centralizes and streamlines management of the VNA and related systems by using standardized bidirectional messaging to facilitate communications across systems, consolidating maintenance, and reducing costs and time, TeraMedica said.
Evercore 6.0 can be used to track patient clinical trends, departmental performance, and the status of its own VNA hardware and software.
[[{"type":"media","view_mode":"media_crop","fid":"29690","attributes":{"alt":"TeraMedica Evercore 6.0","class":"media-image media-image-right","id":"media_crop_9343794194810","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3089","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 222px; width: 440px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"TeraMedica's Evercore 6.0","typeof":"foaf:Image"}}]]
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the recent RSNA conference.
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.
